The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Fixed-duration combinations for first-line CLL treatment—what do the long-term trial results show?
Featured:
Paolo GhiaDuring the 17th International Conference on Malignant Lymphomas (ICML), the Lymphoma Hub spoke with Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked, What do the long-term trial results show for fixed-duration combinations in first-line chronic lymphocytic lymphoma (CLL) treatment.
Fixed-duration combinations for first-line CLL treatment—what do the long-term trial results show?
Ghia discusses RESONATE (NCT01578707) and CAPTIVATE (NCT02910583), two long term follow-up studies highlighted at ICML evaluating ibrutinib with venetoclax or ofatumumab as a fixed therapy in patients with CLL. Key conclusions discussed are the incidence of adverse events, progression-free survival and overall survival, time to next treatment, and impact of minimum residual disease. He describes these data as favorable for patients with CLL and explains that minimum residual disease status impacts response rates. Further study is required to investigate follow-up treatment options if patients are seen to relapse after 6 years.